← Dashboard
Stock
EW
EDWARDS LIFESCIENCES CORPORATIONHealth CareHealth Care EquipmentLatest close $828 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
8
27 funds tracked
Ever held
14
Current + past
New this quarter
2
Exited this quarter
1
Marquee-fund ownership over time
Nov 13, 2013Nov 13, 2018May 17, 2021May 15, 2026
Now
8
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2013 | 51Q | $11 | $82 | +676% |
| Viking Global Investors re-entered | Q4 2019 | 27Q | $81 | $82 | +2% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $67 | $82 | +24% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $67 | $82 | +24% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $67 | $82 | +24% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $67 | $82 | +24% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $67 | $82 | +24% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $67 | $82 | +24% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| D.E. Shaw 2× in & out | Q1 2026 | Q2 2026 | → $81 | +4% |
| Soros Fund Management | Q4 2024 | Q2 2025 | → $77 | +16% |
| Maverick Capital 5× in & out | Q4 2024 | Q1 2025 | → $76 | +15% |
| D1 Capital Partners | Q2 2021 | Q1 2022 | → $108 | +20% |
| Glenview Capital | Q2 2020 | Q4 2020 | → $82 | +16% |
| JANA Partners | Q1 2014 | Q2 2014 | → $14 | +27% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Edwards Lifesciences Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
31
Filings · last 90d
37
Total on file
714
Recent SEC buffer
Most recent
May 29, 2026
30d / 90d windows measured from May 29, 2026 — the most recent Form 4 on file — not from today.
- Form 40001225208-26-005647May 29, 2026
- Form 40001225208-26-005610May 27, 2026
- Form 40001225208-26-005576May 22, 2026
- Form 40001225208-26-005464May 18, 2026
- Form 40001225208-26-005463May 18, 2026
- Form 40001225208-26-005172May 12, 2026
- Form 40001225208-26-005171May 12, 2026
- Form 40001225208-26-005170May 12, 2026
- Form 40001225208-26-005133May 11, 2026
- Form 40001225208-26-005132May 11, 2026
- Form 40001225208-26-005131May 11, 2026
- Form 40001225208-26-005130May 11, 2026
- Form 40001225208-26-005055May 8, 2026
- Form 40001225208-26-005054May 8, 2026
- Form 40001225208-26-005053May 8, 2026
Showing 15 of 714 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · EDWARDS LIFESCIENCES CORPORATIONAnnual figures sourced directly from EDWARDS LIFESCIENCES CORPORATION's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$6.07B
FY2025+12% YoY
Net income
$1.07B
FY2025-74% YoY
EPS (diluted)
$1.83
FY2025-74% YoY
Free cash flow(?)
$1.34B
FY2025+361% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Edwards Lifesciences Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 8, 2026
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 4, 2026
- 8-KMaterial eventApr 23, 2026
- DEF 14AProxy statementMar 26, 2026
- 10-KAnnual reportFeb 25, 2026
- 8-KMaterial eventFeb 10, 2026
- 8-KMaterial eventJan 12, 2026
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventAug 19, 2025
- 10-QQuarterly reportAug 6, 2025
- 8-KMaterial eventAug 6, 2025
- 8-KMaterial eventJul 25, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Viking Global Investors | Q2 2026 | open | $81 | $88 | +8% |
| Renaissance Technologies | Q2 2026 | open | $81 | $82 | +1% |
| D.E. Shaw | Q1 2026 | Q2 2026 | $78 | $81 | +4% |
| Viking Global Investors | Q4 2025 | Q1 2026 | $86 | $78 | -9% |
| Point72 Asset Management | Q1 2025 | open | $76 | $82 | +8% |
| Soros Fund Management | Q4 2024 | Q2 2025 | $66 | $77 | +16% |
| Maverick Capital | Q4 2024 | Q1 2025 | $66 | $76 | +15% |
| Renaissance Technologies | Q4 2024 | Q4 2025 | $67 | $86 | +29% |
| Citadel Advisors | Q3 2024 | open | $67 | $82 | +24% |
| Two Sigma Investments | Q3 2024 | open | $67 | $82 | +24% |
| D.E. Shaw | Q3 2024 | Q4 2025 | $67 | $86 | +30% |
| AQR Capital Management | Q3 2024 | open | $67 | $82 | +24% |
| Millennium Management | Q3 2024 | open | $67 | $82 | +24% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $67 | $66 | -1% |
| Maverick Capital | Q4 2022 | Q2 2024 | $74 | $90 | +23% |
| D1 Capital Partners | Q2 2021 | Q1 2022 | $90 | $108 | +20% |
| Bridgewater Associates | Q4 2020 | open | $82 | $88 | +7% |
| Maverick Capital | Q3 2020 | Q1 2021 | $78 | $87 | +11% |
| Glenview Capital | Q2 2020 | Q4 2020 | $71 | $82 | +16% |
| Bridgewater Associates | Q2 2020 | Q3 2020 | $72 | $79 | +8% |
| Viking Global Investors | Q4 2019 | Q2 2020 | $81 | $71 | -12% |
| Bridgewater Associates | Q3 2019 | Q1 2020 | $73 | $76 | +3% |
| Bridgewater Associates | Q4 2018 | Q1 2019 | $49 | $59 | +19% |
| Bridgewater Associates | Q2 2017 | Q2 2018 | $37 | $45 | +24% |
| Maverick Capital | Q3 2016 | Q1 2019 | $38 | $59 | +54% |
| Bridgewater Associates | Q2 2016 | Q1 2017 | $34 | $30 | -12% |
| Bridgewater Associates | Q3 2015 | Q4 2015 | $24 | $25 | +6% |
| Maverick Capital | Q2 2015 | Q4 2015 | $22 | $26 | +18% |
| JANA Partners | Q1 2014 | Q2 2014 | $11 | $14 | +27% |
| Bridgewater Associates | Q4 2013 | Q1 2014 | $11 | $11 | +5% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.